A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating ...

Natixis Advisors LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 32.1% during ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

We think CR Pharma has a weaker financial position compared with the top three medical distributors. Similar to other pharmaceutical distributors, accounts receivable make up a large portion of its ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...